Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice.
Ali A, Bain S, Hicks D, Newland Jones P, Patel DC, Evans M, Fernando K, James J, Milne N, Viljoen A, Wilding J; As part of The Improving Diabetes Steering Committee. Ali A, et al. Diabetes Ther. 2019 Oct;10(5):1595-1622. doi: 10.1007/s13300-019-0657-8. Epub 2019 Jul 9. Diabetes Ther. 2019. PMID: 31290126 Free PMC article. Review.
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes.
Wheeler DC, James J, Patel D, Viljoen A, Ali A, Evans M, Fernando K, Hicks D, Milne N, Newland-Jones P, Wilding J; as part of the Improving Diabetes Steering Committee. Wheeler DC, et al. Among authors: ali a. Diabetes Ther. 2020 Dec;11(12):2757-2774. doi: 10.1007/s13300-020-00930-x. Epub 2020 Sep 29. Diabetes Ther. 2020. PMID: 32996085 Free PMC article. Review.
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
Davies MJ, Rosenstock J, Ali A, Russell-Jones D, Souhami E, Palmer K, Ji C, Niemoeller E, Skolnik N. Davies MJ, et al. Among authors: ali a. Diabetes Obes Metab. 2022 Jan;24(1):34-41. doi: 10.1111/dom.14543. Epub 2021 Oct 6. Diabetes Obes Metab. 2022. PMID: 34617398 Free PMC article. Clinical Trial.
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review.
Wilding JPH, Evans M, Fernando K, Gorriz JL, Cebrian A, Diggle J, Hicks D, James J, Newland-Jones P, Ali A, Bain S, Da Porto A, Patel D, Viljoen A, Wheeler DC, Del Prato S. Wilding JPH, et al. Among authors: ali a. Diabetes Ther. 2022 May;13(5):847-872. doi: 10.1007/s13300-022-01228-w. Epub 2022 Mar 20. Diabetes Ther. 2022. PMID: 35307801 Free PMC article. Review.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Frías JP, et al. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. N Engl J Med. 2021. PMID: 34170647 Clinical Trial.
11,440 results
You have reached the last available page of results. Please see the User Guide for more information.